We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
Published online by Cambridge University Press: 15 April 2020
The use of antidepressants (AD) in children and adolescents has become controversial due to a possible increased risk of suicide, revised evidence about effectiveness, and growing usage. Several studies have been conducted through healthcare databases, mainly restricted to hospitalized cases.
To evaluate the rate of self-harm among children (10–14 years) and adolescents (15–19 years) who use AD and to compare rates between classes of AD, using a common data model.
A retrospective cohort study was conducted in children and adolescents, age 10–19, members of the Quebec (QC) public drug plan or residents of British Columbia (BC), and who received a new AD treatment in 1997–2008 (QC) and 1997–2006 (BC). Self-harm (fatal or non-fatal) was the main outcome. Data sources consisted of prescription, medical services, and hospitalization databases. AD were categorized into: fluoxetine (only AD approved for paediatric use for depression in Canada), non-fluoxetine SSRIs, TCAs, and others. Multivariate logistic regression analyses were conducted using high dimensional propensity scores.
Were included 51,868 and 28,200 AD users from BC and QC, respectively: 70% were females, and 60% had received a diagnosis of depression. Risk of hospitalization for self-harm was 38.15 and 19.23/1000 person-years in BC and QC, respectively. Rates were higher among adolescents (BC: 47.52; QC: 21.36) than children (BC: 17.00, QC: 12.99). For both hospitalized and non-hospitalized cases, while there was no statistically significant difference in risk associated with fluoxetine relative to non-fluoxetine SSRIs, TCAs were associated with a lower risk in BC (OR = 0.47; 95% CI: 0.31–0.72) and Quebec (OR = 0.41; 95% CI: 0.30–0.46).
In two independent large cohorts, there was no apparent differences in risk across ADs. Lower risk of TCAs may be due to residual confounding by indication.
MT a reçu des honoraires comme orateur par Janssen, BMS, AstraZeneca. YM, LL, BG et TD travaillent comme consultants pour les autorités de régulation et l’industrie pharmaceutique.
You have
Access
To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Find out more about the Kindle Personal Document Service.
To save this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your Dropbox account. Find out more about saving content to Dropbox.
To save this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your Google Drive account. Find out more about saving content to Google Drive.
Comments
No Comments have been published for this article.